Sanders Morris Harris LLC Makes New Investment in Astera Labs, Inc. $ALAB

Sanders Morris Harris LLC bought a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,544 shares of the company’s stock, valued at approximately $4,821,000.

Other institutional investors also recently bought and sold shares of the company. Keating Financial Advisory Services Inc. bought a new position in shares of Astera Labs during the 2nd quarter valued at about $25,000. Archer Investment Corp bought a new stake in shares of Astera Labs in the second quarter worth about $30,000. Transamerica Financial Advisors LLC bought a new stake in shares of Astera Labs in the second quarter worth about $35,000. Continuum Advisory LLC purchased a new stake in shares of Astera Labs in the second quarter worth about $37,000. Finally, GK Wealth Management LLC purchased a new stake in shares of Astera Labs in the third quarter worth about $29,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Astera Labs Trading Down 7.7%

Shares of ALAB stock traded down $25.13 during trading hours on Wednesday, reaching $300.28. 4,579,009 shares of the stock were exchanged, compared to its average volume of 5,172,227. The firm has a market capitalization of $52.10 billion, a price-to-earnings ratio of 148.65 and a beta of 3.68. Astera Labs, Inc. has a 12-month low of $97.89 and a 12-month high of $499.48. The company’s 50-day moving average price is $316.78 and its 200-day moving average price is $294.44.

Astera Labs (NASDAQ:ALAB – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.11. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%. The business had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. The company’s revenue for the quarter was up 104.5% compared to the same quarter last year. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, sell-side analysts expect that Astera Labs, Inc. will post 2.70 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ALAB. Needham & Company LLC increased their price target on Astera Labs from $260.00 to $425.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Jefferies Financial Group raised their price target on Astera Labs from $270.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Stifel Nicolaus lifted their price objective on Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Barclays upped their price objective on Astera Labs from $200.00 to $325.00 and gave the stock an “equal weight” rating in a report on Monday, July 20th. Finally, Citigroup cut Astera Labs from a “buy” rating to a “hold” rating in a report on Friday, October 9th. Eleven analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $348.33.

Check Out Our Latest Analysis on ALAB

Insider Activity

In other Astera Labs news, Director Manuel Alba sold 183,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total value of $51,263,790.00. Following the transaction, the director owned 253,863 shares of the company’s stock, valued at $71,114,642.19. This represents a 41.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stefan A. Dyckerhoff sold 8,994 shares of the stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $376.06, for a total value of $3,382,283.64. Following the completion of the sale, the director owned 2,648 shares in the company, valued at approximately $995,806.88. The trade was a 77.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 408,558 shares of company stock worth $127,306,034 in the last three months. Corporate insiders own 10.40% of the company’s stock.

Astera Labs Company Profile

(Free Report)

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data centers connect and manage processors, memory, storage, and networking components in high-performance computing systems.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) smart memory controllers, Scorpio PCIe switches, Taurus Ethernet fabric switches, and Leo CXL memory connectivity products.

See Also

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.